Science. Service. Solutions.

We are a quality and innovation-led CDMO with over 25 years of experience, committed to helping our clients deliver cell and gene therapies that transform patients’ lives.

We offer end-to-end capabilities, from plasmid design and optimisation, to clinical and commercial CGMP manufacturing, accompanied by robust control systems, analytical methods and deep regulatory knowledge.

Our expertise across lentivirus, AAV, and adenoviral vectors is relied upon by some of the world’s most successful biotechnology and pharmaceutical companies.

Let's talk

>340

CGMP batches released

>50

Audits completed

>30

Process development projects

>70

Qualified assays and methods

About Oxford Biomedica

We believe in pushing the boundaries of scientific possibility and know it takes exceptional knowledge and innovative processes to make that happen.

  • 1st worldwide to administer lentiviral vector gene therapy in vivo
  • 1st commercial supplier of lentiviral vectors for a CAR-T therapy
Read more about us
OXB Manufacturing

Our cell and gene therapy services

We have extensive end-to-end capabilities in lentivirus and AAV vectors, as well as adenovirus systems and can help you design, develop, manufacture and deliver the life-changing medicines of tomorrow.

Discover our services

LentiVector® platform

Achieve reliable and impressive results with our innovative LentiVector® platform, the first commercially approved lentiviral gene delivery technology.

LentiVector® platform

AAV platform

Bring confidence to clinical trials with our proven AAV viral vector development and production process, capable of producing consistently high quality and high titre products.

We have:

  • Demonstrated >E15 vg/L titers
  • Achieved >90% fully intact vector
  • Analytical toolbox with over 45 methods
  • Process scales from 2L to 2000L
  • Six successful IND/CTA filings
AAV

Tech transferred-in

Alongside our own LentiVector® and AAV platform technologies, we have the facilities and expertise to fulfil almost any development need. You define the methods and processes, and we leverage our class-leading capabilities as appropriate.

Latest news

Discover our latest updates.

Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results

 Oxford, UK – 5 March 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today provides an update to its medium-term financial guidance following the recent completion of its acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“the Transaction”), as well as an update on trading for the year ended 31 December 2023.   Additionally, the Company announces that it will report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024.    – Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%  – Projected FY2024 revenue range of £126 million to £134 million, reflecting the successful integration of ABL Europe and anticipated growth from new and existing client programmes  – FY2023 revenues and EBITDA expected to be in line with guidance provided at the Interim Results  – FY2023 Preliminary Results to be reported on Monday, 29 April 2024     Trading update for FY2023 and updated medium-term financial guidance  In line with guidance provided at the Interim Results, revenues for the year ended 31 December 2023 are expected to be approximately £90 million. Operating EBITDA loss for the second half of 2023 is on track to be approximately £10 million better than the first half, as previously guided.  As a result of the Transaction, including the additional revenues expected from the Company’s recently acquired operations in France, revenues for the year ended 31 December 2024 are expected to be between £126 million and £134 million, with revenues for the year being second half-weighted. Furthermore, the Company now expects a three-year revenue CAGR of more than 35% for the years 2023-2026, exceeding the previously communicated figure of more than 30%.  Following the completion of the Company’s streamlining efforts in 2023, including the transition to a global site-based model, Oxford Biomedica reiterates its guidance of achieving broadly breakeven EBITDA in 2024, excluding the impact of the Transaction. Including the impact of the Transaction, the Company anticipates a modest operating loss attributed to the recently acquired French operations. This is expected to be fully funded by the €10 million cash funding in ABL Europe from Institut Mérieux received prior to completion of the Transaction.  The Company confirms that it expects to achieve Operating EBITDA margins in excess of 20% by the end of 2026, as previously guided, and to be profitable on an EBITDA level in 2025.  Liquidity update post ABL Europe acquisition  The cash position at 31 December 2023 was £103.7 million. This excludes the €10 million cash funding in ABL Europe provided by Institut Mérieux upon completion of the Transaction on 29 January 2024. Post completion of the Transaction, Institut Mérieux SA became a 6.2% shareholder. Institut Mérieux will increase their shareholding upon the issuance of new shares pursuant to the subscription agreed as part of the Transaction, which was cash neutral for OXB.  As previously disclosed in the announcement on 20 September 2023, this tranche of funding will provide the Company with €20 million to cover capital expenditure and potential operational losses related to the acquisition of ABL Europe, in exchange for Oxford Biomedica ordinary shares. The shares will be issued prior to 27 September 2024, with timing at Oxford Biomedica’s discretion, at a price being the 30-day VWAP to the day before the date of this subscription.  Continued growth in orderbook for CDMO services  Throughout 2023, OXB continued to grow and diversify its portfolio of clients and programmes with multiple expanded and new agreements signed for the development and manufacture of lentivirus, AAV and adenoviral vectors as well as other vector types.  The contracted value of client orders signed during the year ended 31 December 2023 was £131 million, an increase of more than 50% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing). This increase reflects the improved biotech funding environment, which further instils confidence in the Company’s ability to further expand its backlog and receive orders.  Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “OXB is continuing to successfully deliver its pure-play CDMO strategy. Our expansion into the European Union through the acquisition of ABL Europe strengthens our vector-agnostic service offering and strongly demonstrates our commitment to global client service and excellence. With these developments and our growing order book, we are confident about accelerating our financial performance and fulfilling our updated medium-term guidance.”  Notice of Preliminary Results  OXB expects to report its Preliminary Results for the twelve months ended 31 December 2023 on Monday 29 April 2024. A briefing for investors and analysts will take place at 13:00 BST / 08:00 ET at One Moorgate Place, London, EC2R 6EA.    -Ends-    Enquiries:  Oxford Biomedica plc:  Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 1865 509 737 / E: ir@oxb.com  ICR Consilium:  T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com  Mary-Jane Elliott / Matthew Neal / Davide Salvi  About Oxford Biomedica  Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy contract development and manufacturing organisation (CDMO) with a mission to enable its clients to deliver life changing therapies to patients around the world.  One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.  Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube. 

Read more

Oxford Biomedica completes acquisition of ABL Europe

Oxford, UK – 29 January 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”). Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, US and UK Expands Oxford Biomedica’s ability to serve more clients, unlocking development capacity and increasing revenues 3.2 per cent of the Company’s share capital issued to Institut Mérieux at a share price of 407.4p The acquisition of ABL Europe, a pure-play European CDMO, strengthens Oxford Biomedica’s position as a world-leading cell and gene therapy CDMO. This strategic move broadens the Company’s international development, manufacturing and testing presence, services and capacity by establishing a strong footprint within the European Union with facilities in Lyon and Strasbourg, France. In addition, the acquisition increases Oxford Biomedica’s capacity in process and analytical development and early- stage manufacturing across Adenovirus, Lentiviral vectors, AAVs and with this acquisition, MVA and Vaccinia. Pursuant to the transaction terms, as previously disclosed, ABL Europe has been acquired for a consideration of €15million, (including the value of €10million of pre-completion cash funding from Institut Mérieux in ABL Europe) in exchange for 3,149,374 new ordinary shares in the Company (representing 3.2 per cent of the Company’s enlarged issued share capital) which have been issued at a price of 407.4p. The shares have this morning been admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. In accordance with the terms of the transaction, Institut Mérieux intends to become a major shareholder in Oxford Biomedica and prior to today’s completion of the acquisition of ABL Europe had already built a stake of 3.3 per cent of the Company’s then issued share capital through purchases in the open market, with the intention of owning approximately 10.0 percent of the Company’s ordinary shares by the end of Q3 2024. The Company confirms that there is no material change to the 2023 financial guidance provided at the Interim Results in September previously reaffirmed in the Business Update on 7 December 2023. The Company will in due course issue medium term financial guidance to include the impact of the acquisition. Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “Welcoming ABL Europe into the OXB family is an important step to unlock our ability to serve more clients with existing and new technologies, expanding development capacity, and further broadening our geographical presence. We are also delighted to have Institut Mérieux as a long-term shareholder as we continue to solidify our position as a world leading pure-play quality and innovation-led global cell and gene therapy CDMO.” Michel Baguenault, Chief Executive Officer of Institut Mérieux, said: “Institut Mérieux is delighted that ABL Europe is becoming part of OXB, a world leading cell and gene therapy CDMO. Our investment reflects our confidence in OXB’s potential to ensure ABL’s long-term development. This transaction opens up exciting growth opportunities for ABL Europe, that will significantly expand their offering to biopharma and biotech companies, and ultimately help more patients.”   -Ends-   Enquiries:  Oxford Biomedica plc:  Sebastien Ribault, Chief Commercial Officer  T: +44 (0)7519 109325 / E: partnering@oxb.com  Sophia Bolhassan, VP, Corporate Affairs and IR  T: +44 (0) 7394 562 425 / E: ir@oxb.com  ICR Consilium:  Mary-Jane Elliott / Matthew Neal / Davide Salvi  T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com    About Oxford Biomedica Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

Read more

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing

Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innovation-led cell and gene therapy CDMO, will host a free 60-minute webinar offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors. This event will demonstrate how unique and transferable technical expertise in viral vector development can significantly accelerate the development path and future-proof gene therapy products.  This webinar, titled “Viral Vector Manufacturing Success Stories: Onboarding to GMP Production”, will feature a presentation by:  – Amy Barker, PhD, Principal Scientist, Process Development at Oxford Biomedica,  – Andre Raposo, PhD, Director, Innovation Department at Oxford Biomedica, and  – Hannah Boss, Head of Quality Control at Oxford Biomedica.  Attendees will learn about:  Cutting-edge, end-to-end automation of analytical assays  Design of Experiments to optimize vector production  Considerations for product comparability during process changes  Case studies to demonstrate enhancements to viral vector production and successful process transfer to GMP operations  The webinar will be held at 16:00 GMT / 11:00 EST / 17:00 CET on Wednesday 7 February 2024, followed by a live Q&A session. To register for the webinar, please click here.  More information about Oxford Biomedica’s products and services can be found here.    -Ends-    About Oxford Biomedica  Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.  One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.  Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, and follow us  on LinkedIn and YouTube.    Enquiries:  Oxford Biomedica plc:  Sebastien Ribault, Chief Commercial Officer  T: +44 (0)7519 109325 / E: partnering@oxb.com  Sophia Bolhassan, VP, Corporate Affairs and IR  T: +44 (0) 7394 562 425 / E: ir@oxb.com  ICR Consilium:  Mary-Jane Elliott / Matthew Neal / Davide Salvi  T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com 

Read more

Downloads

Learn about our 4th generation lentiviral vector delivery system and how this latest lentiviral vector technology developed at Oxford Biomedica can significantly enhance the development and manufacture of safer and more effective lentiviral vector based.

 Download

You can also download brochures for our other unique technologies including our TRiP System™ and LentiStable™ cell lines here.

View all

Email alerts

Subscribe to our mailing list

Email Alerts form

Privacy policy(Required)